Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180465 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
A Phase 2 study of Weight, sponsored by Neothetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 2
- Study locations
NCT01180465 is a Phase 2 study of Weight that has completed, run by Neothetics. The registered enrollment target is 160 participants, below the 356-participant average among 5 other Weight trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01180465, a Phase 2 study of Weight, has completed, sponsored by Neothetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
LIPO-102 is under evaluation for treatment of abdominal adiposity
Conditions Studied
Interventions
- DRUG LIPO-102
- DRUG LIPO-102 Low
- DRUG LIPO-102, Placebo
Study Locations (2)
California
- - San Diego
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01180465
The ClinicalTrials.gov registry entry for NCT01180465 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 356-participant average among 5 other Weight trials with a reported enrollment target (55% lower). The listed sponsor is Neothetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Weight appearing as the primary indexed condition, and to 3 interventions - of which LIPO-102 is the first listed.
NCT01180465 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT01180465 about?
NCT01180465 is a clinical study titled "A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity". LIPO-102 is under evaluation for treatment of abdominal adiposity
What is the current status of trial NCT01180465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2010-04. Estimated completion is 2010-09.
What conditions does trial NCT01180465 study?
This clinical trial studies the following conditions: Weight.
What interventions are being tested in trial NCT01180465?
The interventions under investigation include: LIPO-102 (DRUG), LIPO-102 Low (DRUG), LIPO-102, Placebo (DRUG).
Who is sponsoring clinical trial NCT01180465?
This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01180465 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial
RECRUITING · NA
-
PaTH Clinical Data Research Network (CDRN) Study of Healthy Lifestyles and Health Care
ACTIVE NOT RECRUITING
-
A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer
COMPLETED · NA
-
Weight Outlooks by Restriction of Diet and Sleep
COMPLETED · NA
-
Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.